Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.78 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.78 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.78 |
| ▸ | ANPEP | P15144 | 5/20 | 0.69 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820118 | 1.00 | DPP4 (0.78) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL29379602 | 0.90 | DPP4 (0.65) | DPP4NR1H2NR1H3ANPEPKMT2A | |
| SCHEMBL6927281 | 0.88 | DPP4 (1.00) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL17531021 | 0.87 | ANPEP (0.67) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL30954668 | 0.87 | ANPEP (0.67) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL29382416 | 0.87 | DPP4 (0.61) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL6925321 | 0.86 | ANPEP (0.66) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL300362 | 0.86 | DPP4 (0.61) | DPP4NR1H2NR1H3ANPEPKMT2A | |
| SCHEMBL24012151 | 0.84 | DPP4 (0.58) | DPP4NR1H2NR1H3ANPEPFAAH | |
| SCHEMBL13990311 | 0.84 | DPP4 (0.58) | DPP4NR1H2NR1H3ANPEPFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118985448-A | Method for inducing cluster buds to simultaneously increase nodes, increase height and proliferate camellia oleifera | 广西壮族自治区林业科学研究院 | 2024-11-22 | — | — | CN | claimed |
| CN-116389940-A | Remote water meter reading method based on eDRX communication technology | 广西上善若水发展有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026100379-A1 | COMPOSITION, NONLINEAR OPTICAL FILM, METHOD FOR FORMING NONLINEAR OPTICAL FILM, AND OPTICAL MODULATOR | 三菱ケミカル株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102230-A2 | INCREASED NITROGEN FIXATION USING BACTERIA WITH MODIFIED ELECTRON TRANSPORT GENES | Bayer CropScience LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TALLAC THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CONTINEUM THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12559490-B2 | Compositions and methods for modulating hair growth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-PP37267-P3 | Corylus plant named ‘Thompson’ | OREGON STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4680614-A1 | IMPROVED DIRECT SYNTHESIS OF ALKENYLHALOSILANES | Momentive Performance Materials Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12509432-B2 | Alicyclic epoxy compound product | DAICEL CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| CN-108369985-B | Antireflection material | 株式会社大赛璐 | 2022-04-29 | — | — | CN | disclosed |
| US-11293111-B2 | Plating bronze on polymer sheets | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20220089808-A1 | HIGH-PURITY 3,4-EPOXYCYCLOHEXYLMETHYL METHACRYLATE | DAICEL CORPORATION (JP) | 2022-03-24 | — | — | US | disclosed |
| US-20220089822-A1 | BIAXIALLY ORIENTED POLYPROPYLENE FILM | TOYOBO CO., LTD. (JP) | 2022-03-24 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| EP-3955906-A1 | COMBINATION THERAPY COMPRISING AN FFAR4 AGONIST AND AN ALPHA-7 NACHR AGONIST OR POSITIVE MODULATOR | Akershus Universitetssykehus HF (NO) | 2022-02-23 | — | — | EP | disclosed |
| US-20220032602-A1 | ON-PRESS PROCESSING OF A UV OR VIOLET-SENSITIZED LITHOGRAPHIC PRINTING PLATE | ECO3 BV (BE) | 2022-02-03 | — | — | US | disclosed |
| CN-113993513-A | Combination therapy comprising FFAR4 agonist and alpha-7 NACHR agonist or positive modulator | 阿克斯胡斯大学医院HF | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089808-A1 | HIGH-PURITY 3,4-EPOXYCYCLOHEXYLMETHYL METHACRYLATE | MEP1A, MEP1B, FTO | DPP4 4194/4885NR1H2 3004/4885NR1H3 2743/4885 |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | DPP4 1085/4885NR1H2 4476/4885NR1H3 4482/4885 |
| US-12509432-B2 | Alicyclic epoxy compound product | EEF1A1, ECH1, EMC1 | DPP4 4524/4885NR1H2 547/4885NR1H3 711/4885 |
| US-12565501-B2 | Muscarinic acetylcholine M1 receptor antagonists | CHRM1, CHRM2, CHRM3 | DPP4 2211/4885NR1H2 335/4885NR1H3 342/4885 |
| US-12559490-B2 | Compositions and methods for modulating hair growth | PC, MTCH2, MPC2 | DPP4 4057/4885NR1H2 1756/4885NR1H3 2334/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | DPP4 3005/4885NR1H2 430/4885NR1H3 444/4885 |
| US-20260109728-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | UNG, DUT, TYMP | DPP4 1329/4885NR1H2 4272/4885NR1H3 4396/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | DPP4 3600/4885NR1H2 3280/4885NR1H3 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.